Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has achieved another milestone in European medical cannabis. The company received approval for its second medical cannabis extract in Portugal, Tilray Oral Solution THC10:CBD10. This follows the earlier approvals of Tilray Medical whole flower THC 18 and the first cannabis extract in Portugal.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, emphasized the significance of this approval in expanding medical cannabis offerings for Portuguese patients. The company views this as a important step in meeting patient care needs and providing high-quality cannabis products for specific medical conditions.
Tilray Medical operates in over 20 countries, offering a diverse portfolio of EU-GMP certified medicinal cannabis products. The company remains committed to supporting global medical cannabis patient care…
